Posted by Michael Wonder on 04 Dec 2025
FDA approves lisocabtagene maraleucel for relapsed or refractory marginal zone lymphoma
4 December 2025 - Today, the FDA approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, a BMS Company) for adults with relapsed or refractory marginal zone lymphoma who have received at least two prior lines of systemic therapy.
Efficacy was evaluated in the TRANSCEND FL-MZL Cohort, an open-label, multi-centre, single-arm trial in adults with relapsed or refractory marginal zone lymphoma who had received at least two or more lines of systemic therapy or who relapsed after haematopoietic stem cell transplantation.
